It's striking--bordering on shocking--how investors have reacted differently to the megamergers by Pfizer and Merck, Motley Fool says. Merck traded down right after the announcement, but investors have bid up the stock by 17 percent since Merck announced it would by Schering; conversely, Pfizer's shares are down 18.3 percent. Report
